New combo shows promise for Tough-to-Treat stomach cancer
NCT ID NCT03686488
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times
Summary
This study tested whether combining two drugs, TAS 102 and ramucirumab, is safe and works for people with advanced stomach or gastroesophageal junction cancer that no longer responds to other treatments. 23 participants were enrolled. The goal was to see how long they lived and how long the cancer stayed under control. This is a disease control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.